Skip to main content
Top

Cancer Causes & Control

Issue 6/2000

Content (11 Articles)

Harvard Report on Cancer Prevention Volume 4: Harvard Cancer Risk Index

G.A. Colditz, K.A. Atwood, K. Emmons, R.R. Monson, W.C. Willett, D. Trichopoulos, D.J. Hunter

Changing patterns of tonsillar squamous cell carcinoma in the United States

Morten Frisch, Henrik Hjalgrim, Ane Bonnerup Jæger, Robert J. Biggar

Patterns of inpatient surgeries for the top four cancers in the United States, National Hospital Discharge Survey, 1988–95

Phyllis A. Wingo, Jodie L. Guest, LaMar McGinnis, Daniel S. Miller, Carmen Rodriguez, Cheryll J. Cardinez, Brian Morrow, Michael J. Thun

A graded work site intervention program to improve sun protection and skin cancer awareness in outdoor workers in Israel

Esther Azizi, Pazit Flint, Siegal Sadetzki, Arie Solomon, Yehuda Lerman, Gil Harari, Felix Pavlotsky, Avraham Kushelevsky, Ronen Glesinger, Esther Shani, Lior Rosenberg

Breast cancer risk and lifetime leisure-time and occupational physical activity (Sweden)

Tahereh Moradi, Olof Nyrén, Matthew Zack, Cecilia Magnusson, Ingemar Persson, Hans-Olov Adami

Weight change and risk of postmenopausal breast cancer (United States)

Amy Trentham-Dietz, Polly A. Newcomb, Kathleen M. Egan, Linda Titus-Ernstoff, John A. Baron, Barry E. Storer, Meir Stampfer, Walter C. Willett

Parental smoking, CYP1A1 genetic polymorphisms and childhood leukemia (Québec, Canada)

Claire Infante-Rivard, Maja Krajinovic, Damian Labuda, Daniel Sinnett

Colon cancer screening, lifestyle, and risk of colon cancer

Martha L. Slattery, Sandra L. Edwards, Khe Ni Ma, Gary D. Friedman

The cancer-preventive potential of Panax ginseng: a review of human and experimental evidence

Hai Rim Shin, Joon Youn Kim, Taik Koo Yun, Gareth Morgan, Harri Vainio

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine